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Abstract
Background: Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated
great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties
designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death through the release of
danger-associated molecular pattern molecules (DAMPs), LTX-315 is capable of reshaping the tumor
microenvironment, turning “cold” tumors “hot” through a significant increase in tumor-infiltrating lymphocytes.
Methods: We investigated the potential of LTX-315 to be used in combination with standard-of-care
chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1
mammary fat pad model. Tumor growth curves were compared using one-way ANOVA analysis of variance and
Tukey’s multiple comparisons test, and animal survival curves were compared using the log-rank (Mantel-Cox) test.
We considered p values ≤0.05 to indicate statistical significance.
Results: We found that LTX-315 displayed a strong additive antitumoral effect when used in combination with
CAELYX®, and induced immune-mediated changes in the tumor microenvironment, followed by complete
regression in the majority of animals treated. Furthermore, imaging techniques and histological examination
showed that the combination induced strong local necrosis, followed by an increase in the infiltration of CD4+ and
CD8+ immune cells into the tumor parenchymal tissue.
Conclusions: Our data demonstrate that LTX-315 is a promising combination partner with CAELYX® for the
treatment of triple-negative breast cancer.
Keywords: Triple-negative breast cancer, Immunochemotherapy, Combination therapy, Immunotherapy, Oncolytic
peptide, LTX-315, Doxorubicin, DAMPs, ICD
Background
Breast cancer remains one of the four major cancers,
and is expected to account for approximately 30% of all
new cancer diagnoses in women in the USA, making it
the leading cause of cancer-related deaths in women
aged 20–59 years [1]. Triple-negative breast cancer
(TNBC) represents 15% of breast carcinomas, a particu-
larly aggressive and heterogeneous subtype defined by
the absence of the three primary breast cancer bio-
markers - estrogen receptor (ER), progesterone receptor
(PR) and human epidermal growth factor receptor 2
(HER2, also known as ERBB2). Triple-negative breast
cancer is recognized by high proliferative activity, in-
creased immune cell infiltration, and a more basal-like
and mesenchymal phenotype. Patients with TNBC do
not benefit from endocrine or anti-HER2 therapy, leav-
ing chemotherapy as the only established option [2].
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Resistance usually develops after an initial period of re-
sponse [3]. Hence, there is an urgent need for innovative
treatment options that can improve disease outcome or
complement existing therapies for patients with breast
cancer. With the introduction of immune-based therap-
ies, such as checkpoint blockade, significant advances
have been made in the treatment of cancer, thereby illus-
trating the importance of harnessing the immune sys-
tem. However, immunotherapy has shown limited
success in the treatment of breast cancer [4]. The next
step to further increase the clinical benefit of breast can-
cer therapy will be to target the antitumor immune re-
sponse at multiple levels, which may be accomplished
through combination therapy approaches. Turning cold
tumors hot would further augment the antitumor effi-
cacy of established therapies such as checkpoint block-
ade [5]. By using immune-based combination therapy it
is possible to shift the clinical response to a durable re-
sponse due to immunological memory [6].
Host defense peptides, commonly denoted as cationic
antimicrobial peptides (CAPs) [7], often possess antican-
cer and immune-modulating properties due to their
amphipathic nature and cationic charge. Several CAPs
have been shown to target cancer cells by interacting
with and destabilizing anionic lipid membranes or highly
negatively charged intracellular targets such as mito-
chondria [8], thus emphasizing their potential as novel
anticancer agents [9–15]. We have previously described
the development of LTX-315, a first-in-class oncolytic
peptide used for intratumoral treatment of solid tumors
[16, 17]. The mode of action is associated with a reshap-
ing of the tumor microenvironment, in which LTX-315
induces immunogenic cell death through a membranoly-
tic effect (necrosis), as well as direct effects on intracel-
lular targets such as mitochondria [18–21]. Changes to
the tumor microenvironment are dependent on the re-
lease of potent danger-associated molecular pattern mol-
ecules (DAMPs) and tumor antigens that recruit and
activate dendritic cells with subsequent T-cell activation
and tumor-specific immune responses. Intratumoral
treatment with LTX-315 results in growth inhibition,
complete regression and long-lasting tumor-specific im-
mune responses in a variety of different experimental
animal models [22–24].
Conventionally, chemotherapeutic agents have been
used in the clinic based on their capacity to directly kill
proliferating cells. However, although high-dose chemo-
therapy has been shown to significantly debulk the
tumor, it often leads to disease relapse and the establish-
ment of drug resistance. There is now a growing focus
on a new therapeutic paradigm using low-dose or
medium-dose chemotherapeutics at short repeated inter-
vals due to their potential to stimulate anticancer im-
mune responses while selectively eliminating
immunosuppressive cells [25]. For this reason, chemo-
therapy may be a promising candidate in combination
with immunotherapy, defined as immunochemotherapy,
as shown by augmented anticancer effects following
treatment with chemotherapy and anticancer vaccines
[26, 27]. Furthermore, doxorubicin has been shown to
induce immunogenic cell death in addition to inhibit
suppressive cells such as myeloid-derived suppressor
cells, thereby removing the brakes implemented on the
immune system by such cells [28–30].
In the present study, we investigated the potential of
combining intratumoral treatment with LTX-315 and
CAELYX® (liposomal doxorubicin) in a preclinical TNBC
model. The unique mode of action of LTX-315, repro-
gramming and reshaping the tumor microenvironment,
thus turning “cold” tumors into “hot” tumors, showed a
significant additive antitumor effect when combined
with CAELYX®. It is well-established that
tumor-infiltrating CD8+ T cells are important for thera-
peutic efficacy, and help predict clinical outcome in
breast cancer [5, 31]. LTX-315 induced an increase in
the infiltration of cytotoxic CD8+ T cells into the viable
tumor bed, creating an immunogenic antitumor micro-
environment. Combining LTX-315 with doxorubicin fur-
ther augmented this effect.
Methods
Aim and study design
The aim of this study was to investigate the antitumor
efficacy of LTX-315 in combination with CAELYX® in a
preclinical TNBC animal model (experiment 1, Fig. 1).
Additive antitumor effects were monitored by tumor
size, imaging, histology and survival. Experiment 2 was
designed to mimic the clinical situation, and evaluate
whether larger 4 T1 tumors could be eradicated in a
neoadjuvant setting, combining LTX-315 and CAELYX®
with surgery (experiment 2, Fig. 1).
Cell lines and reagents
The 4 T1 (ATCC, CRL-2539), a murine triple-negative
breast cancer cell line was purchased from the American
Type Culture Collection (ATCC-LGC Standards, Rock-
ville, MD, USA). The 4 T1 cell line is used as an animal
model for stage IV human breast cancer. The cells were
transduced using pCDH-EF1α-extGlucT2A-mKate-NG
FR (gift of Dr Irmela Jeremias Helmholtz Zentrum
München, Munich, Germany). Third-generation pack-
aging plasmids pMDLg/pRRE, pRSV-Rev, and pMD2-G
(Addgene, Teddington, UK) were used. High-titer ves-
icular stomatitis virus (VSV) G-protein-pseudotyped
lentivector was prepared by transient 4-plasmid transfec-
tion of 293 T cells using a TurboFect Transfection Re-
agent (Thermo Scientific, Waltham, MA, USA).
LTX-315 (K-K-W-W-K-K-W-Dip-K-NH2) was produced
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and purchased on request from Bachem AG (Bubendorf,
Switzerland). CAELYX® (pegylated liposomal doxorubi-
cin hydrochloride, 2 mg/ml) was purchased from the
Hospital Pharmacy at Oslo University Hospital –
Radiumhospitalet.
Animals
Female Balb/C wild-type mice, 5–6 weeks old, were ob-
tained from Janvier Labs, Le Genest-Saint-Isle, France.
During the experiments, mice weighing 18–25 g were
kept in groups of 8–10 animals per cage under
climate-controlled conditions, with 12-h light/dark cy-
cles and an ambient temperature. Animals were housed
in suitable cages with free access to standard rodent
chow and water ad libitum. The animals were anesthe-
tized during the experimental procedures with 5% sevo-
fluran as an induction dose and 3–4% as a maintenance
dose during imaging or surgery, which provided a suffi-
cient degree of sedation and analgesia. The animals were
monitored daily and tumor-bearing mice with large tu-
mors were euthanized with cervical dislocation. All pro-
cedures performed were conducted under FOTSid 7214
and 9458, and approved by the Experimental Animal
Board under the Ministry of Agriculture of Norway and
in compliance with The European Convention for the Pro-
tection of Vertebrate Animals used for Experimental and
other Scientific Purposes. The laboratory animal facilities
are subjected to a routine health-monitoring program,
and were screened for common pathogens according to a
modification of the Federation of European Laboratory
Animal Science Association’s recommendation.
Tumor challenge
Tumor cells were harvested, washed in PBS and injected
into the 4th inguinal mammary fat pad on the
right-hand side of syngeneic recipient mice as follows. A
small incision was made to the ventral skin using a scal-
pel, and the skin was deflected using suitable surgical in-
struments to access the mammary fat pad. The
mammary fat pad was then fixated using Kelly forceps
and injected with 2 × 104 4 T1 cells per mouse/20 μl PBS
using Braun Omnican 50 insulin syringes (VWR Inter-
national AS, Oslo, Norway). Finally, the surgical incision
was closed using Polysorb™ braided absorbable suture 5–
0 from Medtronic (Oslo, Norway) and Histoacryl® bio-
logical glue from B. Braun (Melsungen, Germany). The
tumor volume was measured using an electronic caliper
and expressed as volume V = (L × W × W)/2, where V is
Fig. 1 Experimental protocols. Freshly harvested 4 T1 tumor cells were injected into the mammary fat pads of syngeneic (Balb/C) mice. One week
after transplantation, the mice were randomized into four treatment groups: (i) vehicle (saline), (ii) CAELYX®, (iii) LTX-315, and (iv) LTX-315 +
CAELYX® for experiment 1 and (i) vehicle (saline) + surgery, (ii) CAELYX® + surgery, (iii) LTX-315 + surgery, and (iv) LTX-315 + CAELYX® + surgery for
experiment 2
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the tumor volume, W is the tumor width and L is the
tumor length. The animals were euthanized when the
tumor volume reached 1600 mm3 or when tumor ulcer-
ation and/or severe metastasis developed.
Peptide treatment
Palpable tumors (40–80 mm3 on day 7 or 8) were
injected intratumorally with single doses of LTX-315 in
saline (0.5–1.0 mg peptide/50 μl saline) once a day for 2–
3 consecutive days (see Fig. 1). The vehicle control was
saline only (0.9% NaCl in sterile H2O).
Chemotherapy treatment
Treatment with CAELYX® was initiated on the same day
as LTX-315 treatment (see Fig. 1). Animals with palpable
tumors (40–80mm3 on day 7 or 8) were injected intra-
venously with a single dose of CAELYX® (8 mg/kg) in a
volume of 200 μl.
Neoadjuvant treatment and surgery
Animals with larger tumors (60–100mm3 on day 8) were
treated as previously described and anesthetized to surgi-
cally excise tumors on day 14 (day 6 post-treatment). Fol-
lowing a small incision to the skin the tumor was
removed using suitable surgical equipment. All blood ves-
sels were closed using a BOVIE Disposable Cautery Pen
(Agntho’s AB, Lidingö, Sweden). Last, the surgical incision
was closed using Polysorb™, a braided absorbable suture
5–0 from Medtronic (Oslo, Norway) and Histoacryl® bio-
logical glue from B. Braun (Melsungen, Germany). Ani-
mals that underwent surgery were given Temgesic (from
the Hospital Pharmacy at Oslo University Hospital –
Radiumhospitalet) subcutaneously (s.c.) twice per day at
8-h intervals (100 μl using a stock solution of 0.3 mg/ml
diluted 1:10 in sterile H2O).
Bioluminescence imaging (BLI)
For bioluminescence in vivo imaging mice were anesthe-
tized with sevoflurane as previously described. Tumor
growth was monitored using a field of view of 12.5 cm
with binning 8, f/stop 1 and an open filter setting using
the IVIS Spectrum In Vivo Imaging System (Perkin
Elmer, MA, USA). Mice were injected with 200 μl/ani-
mal D-Luciferin (20 mg/ml; Biosynth, Staad,
Switzerland) intraperitoneally 10 min before imaging was
initiated and ventral images were taken. Images were
taken once weekly, starting at treatment baseline (day 7
or 8). The imaging data were then analyzed using the
Living Image software (Perkin Elmer, MA, USA), as radi-
ance photons/sec/cm2/steradian (p/sec/cm2/sr).
Magnetic resonance imaging (MRI)
MRI was performed using a 7 T MR system (Bruker
BioSpin MRI GmbH, Ettlingen, Germany, software
ParaVision 6.0). Three animals from each group were
anesthetized with sevofluran and scanned. The animals
were placed in the prone position in the scanner, with
an abdominal pressure-sensitive probe and a rectal
temperature probe (both Small Animal Instruments,
Inc., Stony Brook, NY, USA) to monitor respiration rate
and temperature. This was connected to the Model 1030
Monitoring & Gating System (Small Animal Instru-
ments, Inc.). The body core temperature of the mice was
kept at approximately 37 °C using a fan module
(MR-compatible Small Rodent Heater System, Small
Animal Instruments, Inc.) adjusting the hot air flow
automatically to keep the temperature stable. To help
ensure the correct placement of the mice and to localize
the tumor, a fast gradient echo localizer scan was per-
formed. For volume measurements, an axial
T2-weighted fast spin echo sequence (repetition time
(TR) = 3000 ms, echo time (TE) =31.05 ms, field of view
= 30 × 30mm2, image matrix = 256 × 256, slice thickness
= 0.5 mm, and slice spacing = 0.2 mm), using a mouse
quadrature volume coil, was used. The whole tumor vol-
ume was covered using 10–12 slices, with the slice
representing the largest diameter of the tumor chosen
for representative images. All images were analyzed
using OsiriX Lite v.8.0.1 software from Pixmeo SARL,
Switzerland.
Histology/immunohistochemistry
Formalin-fixed and paraffin-embedded tissue sections
were deparaffinized in Neo-Clear and graded alcohols,
hydrated, and washed in PBS. After antigen retrieval in a
sodium citrate buffer (pH 6) in a microwave oven, the
endogenous peroxidase was blocked by 0.3% H2O2 for
15 min. Sections were incubated overnight at 4 °C with
primary antibody, rabbit monoclonal anti-CD4 (clone
ab183685, Abcam) or rabbit monoclonal anti-CD8
(clone ab209775, Abcam). As a secondary antibody, the
anti-rabbit-horseradish peroxidase SignalStain® Boost
IHC Detection Reagent (Cell Signaling Technology)
from Dako was used. A matched isotype control was
used as a control for nonspecific background staining.
Flow cytometry
Tumors were surgically excised on day 7 post treatment
following a single intratumoral injection of LTX-315, a
single dose of CAELYX® given intravenously, or the
combination of both. Tumor tissue was processed by
cutting it into small pieces with scissors before being
digested in 2.35ml RPMI-1640 containing 100 μl Enzyme
D, 50 μl Enzyme R, and 12.5 μl of Enzyme A, at 37 °C for
90min according to the manufacturer’s instructions
(mouse tumor dissociation kit from MACS Miltenyi Bio-
tec). The enzymatic reaction was terminated by the
addition of excess PBS before single-cell suspensions were
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prepared by passaging the mixture through 70-μm
nylon cell strainers (BD Falcon, VWR, Norway). After
washing, cells were stained with a live/dead marker
using the LIVE/DEAD™ Fixable Yellow Dead Cell
Stain Kit (Thermofisher Scientific, USA) before block-
ing the FcγIII (CD16) FcγII (CD32) receptors to pre-
vent unspecific binding using the Mouse BD Fc
Block™ (clone 2.4 G2, BD Biosciences Europe,
Norway). Following Fc blockade surface staining was
performed for CD45 allophycocyanin (APC) (clone
30-F11), CD3 phycoerythrin (PE) (clone 145-2C11),
CD4 PerCP-Cy 5.5 (clone RM4–5) and CD8a fluores-
cein isothiocyanate (FITC) (clone 53–6.7) (all from
BD Biosciences Europe, Norway) at 4 °C for 25 min.
Data were acquired using a FACSCanto II flow cyt-
ometer (BD Biosciences) with the BD Biosciences
FACSDiva Software (version 8.0.1) and analyzed using
FlowJo Software (version vX.0.7).
Statistical analysis
Tumor growth curves were compared using one-way ana-
lysis of variance (ANOVA) and Tukey’s multiple compari-
sons test, and animal survival curves (Kaplan–Meier plot)
were compared using the log-rank (Mantel–Cox) test.
Flow data were analyzed using a Student’s t test. We con-
sidered p values ≤0.05 to indicate statistical significance.
Results
LTX-315 shows a significant additive antitumor effect
against 4 T1 mammary carcinomas when combined with
CAELYX®
Animals with palpable 4 T1 mammary carcinomas (40–
60mm3) were treated twice intratumorally with
LTX-315 (1 mg peptide/injection), in combination with a
single dose of CAELYX® intravenously (8mg/kg body
weight). Animals did not display any significant decrease
in body weight in the combination group compared to ei-
ther monotherapy alone, thereby indicating no major in-
crease in adverse events (Fig. 2a). Tumor growth curves
demonstrated slight initial growth inhibition after treat-
ment with CAELYX® alone. However, the tumors relapsed
shortly thereafter and the animals had to be euthanized
due to their tumor burden around day 40–50. LTX-315
monotherapy had no significant impact on tumor growth
due to the sub-therapeutic treatment regime used in this
study. In highly aggressive tumor models, such as the 4 T1
Fig. 2 Local treatment with LTX-315 shows a significant additive antitumor effect when combined with CAELYX®. Animals with established 4 T1
mammary carcinomas were divided into four groups, (i) vehicle controls, (ii) CAELYX®, (iii) LTX-315, or (iv) a combination of LTX-315 and CAELYX®.
Palpable tumors were injected twice intratumorally with 1 mg LTX-315 on day 7 and 8 post tumor challenge and 8mg/kg CAELYX® on day 7. The
body weight of all animals remained within the normal range throughout the study (a). Tumor growth curves showed that LTX-315 had a
significant additive antitumor effect (Tukey’s multiple comparisons test, p≤ 0.05) when combined with single-dose CAELYX® compared to
monotherapy alone (b), in addition to inducing complete regression in 50% of the treated animals (c), as shown by the Kaplan–Meier survival
plot (p < 0.0001)
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model, the optimal treatment regime is numerous con-
secutive injections (three to five) to ensure tumor control
and debulking. Interestingly, the combination of LTX-315
and CAELYX® had an additive effect, as there was signifi-
cant tumor growth inhibition and complete regression in
50% of the treated animals (Fig. 2b and c). Statistical ana-
lysis (Tukey’s multiple comparisons test) revealed the
combination treatment to exhibit significant additive anti-
tumor effects compared to either monotherapy (p ≤ 0.05).
The median survival was 25 days in the control and
LTX-315 group, 35 days in the CAELYX® group, and 64.5
days in animals treated with the combination approach.
Animals from the different treatment groups were ana-
lyzed for tumor growth, using BLI and MRI (Fig. 3a and b,
respectively). As shown by the MRI, control tumors grew
rapidly until the tumor burden endpoint (days ~ 20–30).
Animals treated with CAELYX® alone experienced tumor
growth inhibition for ~ 2 weeks post treatment (day 21)
before 4 T1 tumors relapsed and continued to proliferate.
The sub-therapeutic intratumoral treatment with
LTX-315 induced significant tumor necrosis and debulk-
ing of the tumor. Even so, residual breast cancer cells con-
tinued to grow and the disease relapsed. The combination
of LTX-315 and CAELYX® induced strong debulking of
a
b
Fig. 3 LTX-315 in combination with single-dose CAELYX® induced complete regression of tumors in the majority of animals. Representative
bioluminescent (a) and magnetic resonance (b) images from animals treated with vehicle, CAELYX® alone, LTX-315 alone, or LTX-315 in
combination with CAELYX®. Baseline was defined as day 7, and the study was performed as illustrated in experiment 1 in Fig. 1. Animals were
scanned at the regular interval of once per week
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the tumor, thus resulting in significant tumor growth in-
hibition and complete regression in 50% of the animals, as
seen by the images in Fig. 3.
Combination treatment induces necrosis and T cell
infiltration
Tumors from all treatment groups (n = 4) were harvested
for histological examination on day 6 post treatment (day
13) and on day 20 post treatment (day 27). Tumors were
stained for infiltration of CD3+ (data not shown), CD4+
and CD8+ cells into the peritumoral or intratumoral envir-
onment following treatment. Representative images
showed that control tumors were viable and proliferating
on day 13 and 27. Tumors treated with CAELYX® alone
and LTX-315 alone had areas of significant necrosis and
hemorrhagic damage at both time points (Fig. 4, top panel,
black arrows). LTX-315 monotherapy induced significantly
more necrosis and tumor tissue damage compared to
CAELYX® alone. However, there was viable tumor tissue
with both monotherapies on day 13 and 27. The
combination treatment induced massive necrosis and
tumor debulking, hence resulting in little or no signs of vi-
able tumor tissue on day 27 (Fig. 4). Control tumors
showed that CD4+ T cells were excluded from the tumor
parenchyma on day 13 with low infiltration into the viable
tumor tissue on day 27. CAELYX® treatment alone resulted
in a decrease in the CD4+ population on day 13, before re-
growth of the tumor and a significant increase in the CD4
+ population on day 27. There was significantly greater
intratumoral infiltration of CD4+ T cells in the LTX-315
alone and combination group on day 13 compared to
CAELYX® alone and the control group. The biggest differ-
ence was observed in the amount of tumor-infiltrating
CD8+ T cells. There were low to moderate amounts of
intratumoral CD8+ T cells in the viable tumor tissue in the
control group and monotherapy groups. Significantly lar-
ger amounts were observed in the combination group in
the remaining viable tumor tissue on day 13, indicating re-
shaping of the tumor microenvironment following com-
bination treatment with LTX-315 and CAELYX®.
Fig. 4 Combination treatment with LTX-315 and CAELYX® induced extensive necrosis and tumor tissue damage followed by an increase in CD8+
tumor-infiltrating T cells into the viable tumor region. Tumors (n = 4–5) were harvested on day 13 and 27, and stained for H&E, CD4+ and CD8+ T
cells. Representative histological pictures show that tumors treated with monotherapies or the combination therapy had areas of significant
necrosis and hemorrhagic damage (black arrows). Treated tumors with remaining viable tumor tissue had significant infiltration of CD4+ T cells
compared to tumors in controls in which CD4+ T cells were excluded from the intratumoral milieu. The combination group had higher amounts
of CD8+ T cells in the viable intratumoral environment on day 13 compared to controls
Camilio et al. Breast Cancer Research            (2019) 21:9 Page 7 of 12
The data from the histological examination were fur-
ther validated using flow cytometry. Eight animals from
each treatment group were treated with LTX-315, CAE-
LYX®, or the combination of both, and analyzed using
flow on day 7 post treatment (day 14). In accordance
with the histology results, the combination treatment in-
duced very strong necrosis and tumor cell killing as
shown by a significantly lower percentage of live
cells (Fig. 5a) in the combination group compared to
controls and monotherapies. Furthermore, LTX-315
alone induced a significant increase in CD45+ im-
mune cells within the tumor parenchyma compared
to control tumors (Fig. 5b). CAELYX® alone also in-
creased the number of CD3+ T cells in the tumor
compared to controls (Fig. 5c), while lowering the
number of CD4+ T cells in the tumor microenviron-
ment compared to controls, monotherapies, and the
combination therapy (Fig. 5d). CAELYX® alone de-
creased the number of CD4+ T cells inside the
tumor parenchyma (Fig. 5d), while CAELYX® and
LTX-315 alone induced a significant increase in
tumor-infiltrating CD8+ T cells (Fig. 5e). A signifi-
cant increase in tumor-infiltrating CD8+ T cells was
not observed in the combination group.
Neoadjuvant treatment with LTX-315 in combination with
CAELYX® induces complete regression and an increase in
overall survival
Animals with larger 4 T1 mammary carcinomas were
treated with the LTX-315 and CAELYX® combination on
day 8 before tumors were surgically excised 6 days later
(day 14). LTX-315 was used in a sub-therapeutic setting
with intratumoral injections of 0.5 mg peptide on day 8,
9, and 10, with an injection dose equal to 50% of the one
used in the first experiment (Fig. 1). The combination of
LTX-315 and CAELYX® followed by surgery led to a sig-
nificant increase in survival compared to monotherapy
or vehicle controls and surgery, indicating an additive
anticancer effect by the combination compared to
monotherapies (Fig. 6). The median survival was 38.5
days in controls, 47 days in the CAELYX® group, 38 days
in the LTX-315 group and 75 days in the animals treated
with the combination. Complete regression was ob-
served in 50% of animals treated with the combination.
Discussion
Cancer therapy has been transformed with recent ad-
vances in immunotherapy. Nonetheless, further thera-
peutic advances are needed, with efforts focusing on
implementing strategies that combine different cancer
treatments. Combination therapy has the potential to
dramatically improve the outcome in patients with can-
cer by harnessing potential synergies that can lead to
better clinical responses and increased survival. Over
time it is expected that combination strategies will be-
come the standard of care for all cancers, although the
discovery of effective combinations is a challenging en-
deavor [32]. One promising strategy is the combination
of immunotherapy and chemotherapy, using immuno-
therapeutic drugs capable of activating antitumor
Fig. 5 Treatment with CAELYX®, LTX-315, and the combination of both reshapes the tumor microenvironment. Tumors (n = 8) were harvested on
day 14 (day 7 post treatment) and stained for an array of immune cell markers before being analyzed by flow cytometry. Images show flow
cytometry determination of live cells (a), CD45+ leukocytes (b), CD3+ T lymphocytes (c), CD4+ T cells (d). and CD8+ cytotoxic T cells (e). Each dot
represents data for one mouse. Student’s t test: *P < 0.05, **P < 0.01, ***P < 0.001
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immunity in combination with chemotherapeutic drugs
capable of inducing immunogenic cell death (ICD), while
at the same time inhibiting cancer-mediated immuno-
suppression [29].
Triple-negative breast cancer (TNBC) is recognized as
a heterogenous, biologically aggressive disease for which
there are few treatment alternatives. There are several
promising therapeutic strategies being explored in phase
I–III clinical studies, but conventional chemotherapy is
still considered the standard of care. Patients with
chemo-resistant TNBC have a poor prognosis, and often
a very rapid onset of metastasis. However, the highly
proliferative status of TNBC also makes it more sensitive
to chemotherapy, hence making it a good candidate for
combination strategies involving chemotherapy and im-
munotherapy, since tumors often have an increased im-
mune cell infiltrate [2, 4].
LTX-315 is a de novo designed oncolytic peptide for
local treatment of solid tumors, capable of reshaping
and reprogramming the tumor microenvironment by
ICD [16, 33]. The peptide has a dual mode of action, in-
ducing cancer cell lysis, by destabilizing and disintegrat-
ing the cellular membrane, and interacting with
intracellular targets such as the mitochondria [18, 20].
To further study the potential of LTX-315 in breast
cancer therapy, orthotopical 4 T1 mammary carcinomas
were established in syngenic Balb/C mice, and treated
with LTX-315 and CAELYX® according to the experi-
mental setup illustrated in Fig. 1. In animals, the 4 T1
cells had highly aggressive properties, forming rapidly
growing carcinomas metastasizing to the lungs. All con-
trol animals were euthanized before day 30 (Fig. 2b) due
to tumor burden or lung metastasis. Sub-therapeutic
treatment with LTX-315 did not inhibit tumor growth
significantly, whereas CAELYX® alone partially inhibited
tumor growth, and resulted in a slight increase in overall
survival (Fig. 2b). Thus, the therapeutic efficacy of either
monotherapy was limited. Interestingly, when LTX-315
and CAELYX® were used in combination, tumor growth
was significantly inhibited and complete tumor regres-
sion was achieved in 50% of the animals, indicating a
strong additive antitumor effect between LTX-315 and
CAELYX® (Fig. 2b), which was verified by statistical ana-
lysis of the different treatment groups (p ≤ 0.05). In the
combination group, 50% of the treated animals were
tumor free, as demonstrated by BLI (data not shown) at
the end of the study on day 80 (Fig. 2c). Altogether, this
suggests a strong and long-lasting antitumor response
able to eradicate both local tumor growth and
metastasis.
The tumor debulking property of LTX-315 was quanti-
fied using BLI and MRI (Fig. 3a and b, respectively). The
MRI demonstrated large necrotic areas within the tumor
microenvironment on day 14 and 21, both with LTX-315
a b
c
Fig. 6 Combination therapy with LTX-315 and CAELYX® induced complete regression of triple-negative breast cancer (TNBC) tumors, and
increased survival when used in a neoadjuvant setting. Animals with larger 4 T1 mammary carcinomas (60–100mm3) were divided into four
groups, (i) vehicle controls + surgery, (ii) CAELYX® + surgery (iii) LTX-315 + surgery, or (iv) a combination of LTX-315 and CAELYX® + surgery.
Palpable tumors were injected intratumorally with 0.5 mg LTX-315 on day 8, 9, and 10 post tumor challenge and 8mg/kg CAELYX on day 8.
Tumors were surgically excised (indicated by arrow) 6 days post treatment. The body weight of all animals remained within the normal range
throughout the study (a). Tumor growth curves showed that sub-therapeutic doses of LTX-315 in combination with CAELYX® followed by
surgery, was able to significantly inhibit larger 4 T1 MFP carcinomas (b), and induce complete regression in 50% of the treated animals (c), as
shown by the Kaplan–Meier survival plot (p = 0.0020)
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alone and in the combination group (Fig. 3b). Compar-
ably, CAELYX® alone inhibited tumor growth temporar-
ily, indicating a partial response before recurrence on
day 28. CAELYX® alone did not induce significant tumor
debulking. LTX-315 in combination with CAELYX® in-
duced complete regression of 4 T1 mammary fat pad
carcinomas in several of the treated animals (Fig. 3a and
b). Images from BLI exhibited significant differences in
signal intensity related to the treatment given, thus a
scale bar was not applicable. Treatment with LTX-315
induced local necrosis, leading to leakage and loss of BLI
signal, even though tumors recurred later. For this rea-
son, the intensity of the BLI signal did not always reflect
the measured tumor size and BLI was used primarily as
a method for monitoring metastasis.
To elucidate the mechanism behind the complete re-
gression of tumors treated with the combination, tumor
tissue was analyzed by immunohistochemistry (IHC)
and flow cytometry. Tumor samples for IHC (n = 4)
demonstrated that combination therapy with LTX-315
and CAELYX® induced significant necrosis and
hemorrhagic damage in the 4 T1 TNBC tumors. In
addition, the combination therapy resulted in an in-
crease in tumor-infiltrating CD8+ T cells into the
remaining viable tumor tissue on day 6 post treatment.
On day 27, a majority of the combination animals were
tumor free as illustrated by histological samples showing
no remaining viable tumor tissue (Fig. 4).
Flow cytometry (n = 8) showed that the combination
treatment induced extensive tumor cell killing with very
few live cells 7 days post treatment (Fig. 5a). Further-
more, treatment with LTX-315 alone resulted in a sig-
nificant increase in CD45+ immune cells into the tumor
parenchyma. CD45 is expressed on all leukocytes, in-
cluding neutrophils and natural killer (NK) cells [34].
Given that LTX-315-treatment results in a substantial
increase in CD45+ cells compared to the other treat-
ment groups (Fig. 5b), we speculate that immune cells
other than CD8+ T cells are also important in the
LTX-315-induced antitumor immune response. These
may include CD4+ T helper cells and NK cells. Natural
killer cells have been shown to have an important role in
cancer immunotherapy and are capable of interacting
with and killing cancer cells directly by numerous modes
of action [35]. Treatment with CAELYX® alone reduced
the amount of CD4+ T cells in the tumor microenviron-
ment on day 13 and 14, as demonstrated by both IHC
and flow cytometry (Figs. 4 and 5d, respectively). Thus,
the additive antitumor effects observed when LTX-315 is
combined with CAELYX® may be partially explained by
a reduction in immunosuppressive cells, such as CD4+
regulatory T cells (Tregs) and myeloid-derived suppres-
sor cells (MDSCs). Even though little is known about
the effect of doxorubicin on Tregs, doxorubicin has been
shown to eliminate myeloid-derived suppressor cells
(MDSCs) [28]. Moreover, the down-regulation of CD4+
T cells following treatment with CAELYX® alone seems
to be a transient process, as demonstrated by an increase
in CD4+ T cells on day 27 post treatment (Fig. 4). Treat-
ment with LTX-315 alone and the combination induced
an increase in tumor-infiltrating CD4+ T cells on day 13
and 14 (Figs. 4 and 5d). The increase in tumor-infiltrating
CD4+ T cells following treatment with LTX-315 alone and
the combination, may indicate reshaping of the tumor
microenvironment from immunosuppressive CD4+ Tregs
to a different CD4+ T cell phenotype important for antitu-
mor immunity. CD4+ T helper cells have indeed been
shown to be a critical element in optimal activation of
CD8+ T cells and in the maintenance of cancer-related
immune memory [36–38].
CAELYX® alone induced significant infiltration of CD8
+ cytotoxic T cells compared to the other treatments
(Fig. 5e). The increase in tumor-infiltrating CD8+ T cells
may be related to the amount of viable tumor tissue left
in the treated tumors 7 days post treatment. In the
LTX-315 alone and in the combination group most of
the tumor tissue was necrotic following treatment, com-
pared to tumors treated with CAELYX® alone, which
were less necrotic. In this study, and in previous studies,
we have observed that tumor tissue with substantial ne-
crosis following intratumoral treatment does not contain
significant numbers of CD8+ T cells in the necrotic re-
gion of the tumor, when analyzed by IHC. Accordingly,
we observe extensive infiltration of CD8+ T cells resid-
ing in the remaining viable tumor tissue. Hence, it is
thought that massive necrosis and tumor debulking will
lead to a smaller total number of active CD8+ T cells in-
side the tumor tissue area when analyzed in a quantita-
tive manner.
It is well-established that the location of immune cells
is equally important to the total number of immune
cells, when it comes to the assessment of immunoscore
and patient prognosis and survival [39]. In our study we
observed differences in tumor-infiltrating CD4+ and
CD8+ T cells following treatment with the combination,
when analyzed by IHC and flow (Figs. 4 and 5). Consid-
ering IHC is a snapshot of a specific region of the tumor
parenchyma, while flow cytometry investigates the total
tissue harvested, this is not unexpected. Analysis with
IHC was focused on areas of interest, such as the region
between the treatment-induced necrosis and the viable
tumor tissue. This is the area where CD4+ and CD8+ T
cells will exert their cytotoxic antitumor activity as they
gain access to viable tumor cells. Contrarily, flow cytom-
etry examines the total tissue harvested and does not
differentiate between tumor-excluded or tumor-infiltrat-
ing CD4+ and CD8+ T cells. While IHC is a method that
evaluates compartmentalization of immune cells, which
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is very important for immunoscore and clinical response,
flow cytometry does not. Thus, it is important to analyze
the potential reshaping of the tumor microenvironment
in both a qualitative (IHC) and a quantitative (flow cy-
tometry) manner.
Altogether, these data indicate strong reshaping of the
tumor microenvironment in treated lesions versus
non-treated lesions, thereby resulting in an
immune-mediated antitumor response. This reshaping
of the tumor microenvironment is dependent on the
immunomodulating properties of both LTX-315 and
doxorubicin. Conventional chemotherapeutic agents, in-
cluding doxorubicin, can stimulate the immune system
by directly activating CD8+ or γδ T cells, leading to an
antitumor TH1 response through production of inter-
feron gamma (IFNγ) and IL-17 (reviewed in [40]).
LTX-315 promotes strong local necrosis and ICD
through the release of DAMPs, such as ATP, high mobil-
ity group box 1 protein (HMGB1) and cytochrome c.
DAMPS are important for immune cell activation, anti-
gen presentation, and T cell clonal expansion [16, 18, 40,
41]. This will further induce an intratumoral T cell re-
sponse shown by an increase in CD3+ tumor-infiltrating
lymphocytes (TILs) into the tumor parenchyma [22, 23].
Simultaneously, CAELYX® (doxorubicin) is known to
further promote ICD [42] and inhibit the frequency of
immunosuppressive cells, such as MDSCs [28]. Further-
more, low-dose metronomic doxorubicin has been
shown to inhibit angiogenesis, and inhibit the recruit-
ment of tumor-associated macrophages and cells with
tumor-initiating and treatment-resistant properties [43].
Thus, the additive effect between LTX-315 and CAELYX®
may arise from the ability of LTX-315 to reshape “cold”
tumors into “hot” tumors by stimulating immune activa-
tion and an increase in TILs, which is further augmented
by doxorubicin’s ability to inhibit angiogenesis, induce T
cell infiltration, and deplete immunosuppressive cells [43].
This is also supported by recent evidence demonstrating
the importance of TILs in response to therapy and im-
provement in prognosis in patients with breast cancer [5,
31, 44, 45]. Therefore, the combination of LTX-315 and
CAELYX® demonstrates a potential to alter the tumor
microenvironment in TNBC by converting it from an im-
munologically suppressive microenvironment to a more
immunologically antitumorigenic microenvironment.
To elucidate the potential of LTX-315 in combination
with CAELYX® as a neoadjuvant treatment, 4 T1 breast car-
cinomas were treated 6 days before tumors were surgically
excised from the animals (Fig. 1, experiment 2). At this
point, several of the animals already had metastasis, as dem-
onstrated by BLI (data not shown). Most of the animals in
this study were euthanized due to metastasis (to the lungs),
indicating that a significant increase in survival occurred
due to inhibition of metastasis. Our data demonstrate that
LTX-315, in combination with CAELYX® and surgery, in-
duced a 60–97% increase in median survival compared to
controls or either of the monotherapies and surgery (Fig. 6).
Conclusions
The mode of action of LTX-315 leads to the release of
potent immune stimulators (DAMPs) and tumor anti-
gens, which results in tumor-specific antitumor immune
responses. For this reason, LTX-315 is an ideal candidate
for combination with therapies capable of removing
tumor-induced immune suppression implemented by
suppressive cells such as MDSCs and Tregs. The current
study verifies that LTX-315 has promising potential to
be used in immunochemotherapy, and that such combi-
nations warrant further investigation, aiming for future
clinical implementation.
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